EC
VERA icon

EntryPoint Capital’s Vera Therapeutics VERA Stock Holding History

EntryPoint Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$311K Buy
+7,245
New +$270K 0.08% 538
2024
Q2 		– Sell
-455
Closed -$19.6K – 1879
2024
Q1 		$19.6K Sell
455
-208
-31% -$7.41K 0.02% 1097
2023
Q4 		$10.2K Buy
+663
New +$8.42K 0.01% 1154

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EntryPoint Capital's VERA Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Vera Therapeutics (VERA) in Q2 2026: 7,245 shares worth $311K. The stake represents 0.08% of the portfolio and ranks #538 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in VERA as recently as Q1 2024.

EntryPoint Capital first reported a position in VERA in Q4 2023 and has held it in 3 quarters since. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • EntryPoint Capital held 7,245 shares of Vera Therapeutics worth $311K as of Q2 2026.
  • Vera Therapeutics was a new EntryPoint Capital position in Q2 2026.
  • Vera Therapeutics made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #538 holding.
  • EntryPoint Capital first reported a position in Vera Therapeutics in Q4 2023 and has held it in 3 quarters since.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.